Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaFLO: Pazopanib + FLO in Advanced Gastric Cancer
NCT01503372Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2011
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pazopanib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Progression-Free Survival Rate at 6 months. Started Nov 2011; status: completed.
02
Drugs
pazopanib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01503372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01503372.